ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3
Tango Therapeutics was trading down on Friday after updated results from a mid-stage study of its pancreatic cancer candidate combined…
Tango Therapeutics was trading down on Friday after updated results from a mid-stage study of its pancreatic cancer candidate combined…